7.26.17

ALZHEIMER’S NEWS TODAY: REGENACY’S HDAC BLOCKER IMPROVED COGNITIVE FUNCTION IN MICE WITH ALZHEIMER’S, STUDY SHOWS

A compound that blocks the activity of so-called HDAC enzymes in the brain improved learning in mouse models of Alzheimer’s disease, according to data that Regenacy Pharmaceuticals presented at the recent 2017 Alzheimer’s Association International Conference (AAIC) July 16-20 in London. READ MORE


7.19.17

PRESS RELEASE: REGENACY PHARMACEUTICALS PRESENTS DATA DEMONSTRATING THAT HDAC1,2 INHIBITION IMPROVED COGNITIVE FUNCTION IN MOUSE MODELS OF ALZHEIMER'S DISEASE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE


6.27.17

PRESS RELEASE: REGENACY PHARMACEUTICALS APPOINTS SIMON S. JONES AS PRESIDENT AND CHIEF EXECUTIVE OFFICER


3.08.17

PRESS RELEASE: REGENACY PHARMACEUTICALS DEMONSTRATES REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY WITH HDAC6 INHIBITOR RICOLINOSTAT IN PRECLINICAL MODEL


1.11.17

PRESS RELEASE: REGENACY PHARMACEUTICALS HDAC1,2 INHIBITORS DEMONSTRATE SINGLE-AGENT AND SYNERGISTIC ACTIVITY WITH AZACITIDINE (VIDAZA®) IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA


12.5.16

BIOPHARMADIVE: ACETYLON FORMS REGENACY AHEAD OF CELGENE TAKEOVER

Acetylon Pharmaceuticals is spinning out a new business as the company prepares for Celgene to take it over in a deal worth more than half a billion dollars. READ MORE


12.2.16

PRESS RELEASE: REGENACY PHARMACEUTICALS TO BE LAUNCHED BY ACETYLON PHARMACEUTICALS AND CELGENE CORPORATION AGREES TO COMPLETE ACQUISITION OF ACETYLON


12.2.16

XCONOMY: ACETYLON CRAFTS NEW BUYOUT DEAL WITH CELGENE, SPINS OUT STARTUP REGENACY

Earlier this year, Celgene passed on an exclusive option to buy Acetylon Pharmaceuticals. But surprisingly, the two companies have come up with a new deal instead. Celgene agreed Friday to acquire just a portion of the assets of the Boston company, which will spin the rest of its assets into a new startup called Regenacy Pharmaceuticals. READ MORE